POC1B-GALNT4: A Promising Drug Target / Biomarker (G100528030)

Target Name: POC1B-GALNT4

NCBI ID: G100528030

POC1B-GALNT4

POC1B-GALNT4: A Promising Drug Target / Biomarker

The protein POC1B-GALNT4 is a potential drug target (or biomarker) that has been shown to play a role in a variety of biological processes. POC1B-GALNT4 is a protein that is expressed in many different tissues and cells in the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the GALNT family, which is known for its role in the development and progression of many diseases, including cancer.

The Role of POC1B-GALNT4 in Cancer

One of the primary roles of POC1B-GALNT4 is its role in the development and progression of cancer. Several studies have shown that high levels of POC1B-GALNT4 are associated with the development of many different types of cancer, including breast, ovarian, and colorectal cancers. Additionally, these studies have also shown that POC1B-GALNT4 is involved in the regulation of many cellular processes that are important for cancer growth and progression, including cell division, angiogenesis (the formation of new blood vessels), and immune surveillance.

The Potential therapeutic Use of POC1B-GALNT4

The potential therapeutic use of POC1B-GALNT4 is due to its involvement in the development and progression of cancer, as well as its role in many other cellular processes that are important for disease progression. Because of these properties, POC1B-GALNT4 is a potential drug target (or biomarker) that could be targeted with small molecules or other therapeutic agents.

One of the potential therapeutic approaches for POC1B-GALNT4 is to use small molecules that can inhibit its activity. Many small molecules have been shown to inhibit the activity of POC1B-GALNT4, and these compounds have been shown to be effective in treating a variety of diseases, including cancer. For example, one small molecule, QI, has been shown to inhibit the activity of POC1B-GALNT4 and has been shown to be effective in treating breast cancer.

Another potential therapeutic approach for POC1B-GALNT4 is to use antibodies that can target it specifically. Antibodies are proteins that are produced by the immune system and are designed to recognize and neutralize foreign substances in the body. By using antibodies that are specific for POC1B-GALNT4, it may be possible to target it specifically and inhibit its activity.

Conclusion

POC1B-GALNT4 is a protein that is involved in many different cellular processes that are important for disease progression. Because of its involvement in the development and progression of cancer, as well as its role in many other cellular processes, POC1B-GALNT4 is a potential drug target (or biomarker) that could be targeted with small molecules or other therapeutic agents. Further research is needed to fully understand the role of POC1B-GALNT4 in disease progression and to develop effective therapeutic approaches for its treatment.

Protein Name: POC1B-GALNT4 Readthrough

Functions: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Has a highest activity toward Muc7, EA2 and Muc2, with a lowest activity than GALNT2. Glycosylates 'Thr-57' of SELPLG

The "POC1B-GALNT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POC1B-GALNT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets